Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea

• Published in: Korean journal of pediatrics Vol. 54; no. 4; pp. 146 - 151
• Main Authors: Choi, Eun-Hwa, Kim, Kyung-Hyo, Kim, Yae-Jean, Kim, Jong-Hyun, Park, Su-Eun, Lee, Hoan-Jong, Eun, Byung-Wook, Jo, Dae-Sun, Choi, Kyong-Min, Hong, Young-Jin
• Format: Journal Article
• Language: Korean
• Published: 2011
• Subjects: Pneumococcal conjugate vaccine; Serotype; Streptococcus pneumoniae
• ISSN: 1738-1061; 2092-7258

Streptococcus pneumoniae remains a leading cause of invasive infections including bacteremia and meningitis, as well as mucosal infections such as otitis media and pneumonia among children and adults. The 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among infants and young children in many countries including Korea. The routine use of PCV7 has resulted in a decreased incidence of invasive pneumococcal disease (IPD) by the vaccine serotypes among the vaccinees and substantial declines in IPD among unvaccinated populations such as older children and adults as well. In addition, there are increasing evidences to suggest that routine immunization with PCV7 is changing the epidemiology of pneumococcal diseases such as serotype distribution of IPD, nasopharyngeal colonization, and antibiotic resistance patterns. In contrast, there is an increase in the number of IPDs caused by nonvaccine serotypes, though it is much smaller than overall declines of vaccine serotype diseases. Several vaccines containing additional serotypes have been developed and tested clinically in order to expand the range of serotypes of Streptococcus pneumoniae. Recently two new pneumococcal protein conjugate vaccines, 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13), have been approved for use in several countries including Korea. This report summarizes the recommendations approved by the Committee on Infectious Diseases, the Korean Pediatric Society.